EMA Workshop: working towards new therapies for spinal muscular atrophy
The event will be broadcast live on 11 November
The European Medicines Agency (EMA), Spinal muscular atrophy (SMA) Europe and the TREAT-Neuromuscular diseases (NMD) network are holding a one-day workshop to discuss, support and advance the development of therapies for the treatment of spinal muscular atrophy (SMA). SMA Europe and TREAT-NMD network are two non-profit organisations that bring together patients and academics from Europe and beyond to progress research into SMA and facilitate the development of new therapies.
The workshop will take place at EMA’s premises in London on 11 November 2016, starting at 09:00.
SMA is a rare genetic disease that affects the control of muscle movement. It is caused by a loss of specialised nerve cells, called motor neurons, which results in weakness and wasting (atrophy) of muscles used for activities such as crawling, walking, sitting up, and controlling head movement. Children born with the most serious form of the disease rarely survive beyond the age of two because of severe breathing problems.
At present there is no cure for SMA. Available treatments focus on managing symptoms and preventing complications. However, new therapies are currently being developed and SMA might become one of the first inherited neurological diseases to be successfully treated. A number of experimental therapies are currently being evaluated in early clinical trials and EMA has provided scientific advice to medicine developers on the appropriate tests and studies to be used in the development of medicines for SMA a number of times in the past few years.
The workshop will convene key stakeholders – patients, doctors, industry representatives, researchers and regulators – to take stock of the latest scientific developments in the area and discuss ways of developing therapies for the treatment of SMA. Topics for discussion will include an overview of the disease, the pharmacology of the molecules under investigation, natural history data, clinical outcome measures and potential use of biomarkers in drug development.
- Agenda - EMA - Spinal muscular atrophy workshop (07/11/2016)
Latest News from
Security Union: EC presents new measures to better protect EU citizens19/10/2017 14:27:00
The EC has presented alongside its 11th Security Union Report a set of operational and practical measures to better defend EU citizens against terrorist threats and deliver a Europe that protects.
EU-U.S. Privacy Shield: First review shows it works but implementation can be improved19/10/2017 13:10:00
The EC has published its first annual report on the functioning of the EU- U.S. Privacy Shield, the aim of which is to protect the personal data of anyone in the EU transferred to companies in the U.S. for commercial purposes.
EC opens in-depth investigation into proposed merger of Celanese's and Blackstone's acetate tow activities18/10/2017 16:15:00
The EC has opened an in-depth investigation to assess the proposed creation of an acetate flake and acetate tow joint venture by Celanese and Blackstone under the EU Merger Regulation.
EU approves €100m in financial assistance for Jordan18/10/2017 14:10:00
The EC, on behalf of the EU, has approved the disbursement of a €100m loan to Jordan under its Macro-Financial Assistance (MFA) programme.